Retatrutide
10mg
Retatrutide activates GIP, GLP-1, and glucagon receptors as a triagonist, compounding effects across appetite, glucose metabolism, and hepatic fat oxidation. Phase 2 participants lost up to 24.2% of body weight, with the highest-dose cohort still descending at week 48.
Included free with every order
Bacteriostatic reconstitution solution and sterile dosing needles are included, a $30+ value, always included. Most suppliers charge extra. We never do.
Purity
99.1%
Form
Lyophilized powder
Storage
-20°C
Includes
Solution + needles
Research use only. Not for human consumption. Need help reconstituting? Use our dosing calculator.
Research Outcomes
What The Clinical Data Shows
Based on published peer-reviewed literature. Not medical claims.
24.2%
Peak body weight reduction, a clinical record
48 wks
Study duration, with no plateau reached at endpoint
338
Participants across Phase 2 dose cohorts
Glucagon pathway. Glucagon receptor agonism accelerates hepatic fat oxidation independently of GLP-1's glucose effects, adding a third, distinct fat-loss mechanism.
No plateau observed. The highest-dose cohort showed continued weight loss through week 48 with no plateau, unlike prior single- or dual-agonist compounds.
Liver fat reduction. MRI showed liver fat content reduced by more than 80% in many participants, faster than overall body weight loss.
Strongest responders. Participants with higher baseline insulin resistance responded most, a population that typically underperforms on earlier metabolic compounds.
Research context. All findings are from peer-reviewed literature. Not FDA-approved. Sold for research purposes only. Results in research settings may vary. Not medical advice.